Navigating pharmaceutical partnerships: Choosing your ideal partner
Expanding the reach of your pharmaceutical product into new markets and generating additional revenue requires a reliable out-licensing and export partner. But how do you ensure that your prospective partner’s goals and values align with your own? With a proven track record in out-licensing and export on a global scale, this article shares our insights […]
Reimagining healthcare: How value-added medicines address unmet clinical needs
Addressing unmet clinical needs and evolving patient outcomes require more than conventional approaches; they call for ingenuity, creative solutions, and the ability to see the unseen. Among these innovations, the development of value-added medicines stands out as a unique and transformative approach. Unlike traditional generics, these medicines leverage the potential of known molecules to deliver […]
Colonis becomes a BGMA member
As an innovative company with great ambition to develop value-added medicines and treatment options that benefit patients, we are incredibly proud to be accepted as a full member of the British Generic Manufacturers Association (BGMA).
In-licensing explained: a path to expanding your portfolio
Unlock the potential of in-licensing with Colonis’ vast product range. Explore how pharmaceutical partnerships can enhance your product portfolio.
Strategic out-licensing: maximising the value of your portfolio
In the pharmaceutical industry, breaking into the UK market presents a unique set of challenges; it can be a complex maze of regulatory processes, pricing complexities, and market access hurdles, where local expertise becomes indispensable. That’s why the importance of finding a trusted out-licensing partner cannot be understated. Do you want to discover your full […]
Colonis announce new Alliance and Business Development Manager
The Colonis team are delighted to announce the appointment of Suzie Stratford as Alliance and Business Development Manager. This is a key appointment as Colonis continues to transform existing medicines to create high-quality, value-added medicines, and gives access to those limited by a lack of treatment options on a global scale. Suzie will be responsible […]
Colonis are excited to be attending CPhI 2023 Barcelona
The Colonis team will be attending CPhI Barcelona, taking place on 24th – 26th October 2023. If you are interested in commercialising any of our products in your market or have a product you’re looking to launch in the UK, we would love to meet with you. So, if you are attending please contact us […]
Colonis would like to introduce two new members of our growing team
Colonis are happy to announce that Andy Trouton has recently rejoined the team as Managing Director. With over 35 years of experience in the pharmaceutical industry across brands, generics and unlicensed medicines, Andy will be once again guiding the strategic direction of the Colonis team, providing leadership through development and commercialisation of our novel value-added […]
Colonis unveils new corporate brand, logo and website – a successful innovative pharma company that prioritises unmet patient and clinical needs
Colonis, founded 18 years ago as one pharmacist’s vision to improve the lives of patients, is still prioritising the identification of unique opportunities and repurposing medicines to meet unmet patient and clinical needs. Following acquisition by the Clinigen Group in 2017, Colonis will now operate as a standalone business unit which has resulted in a […]